Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCMA CAR-T cells · 1 trial · 3 indications
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
The response rate of BCMA CAR-T treatment will be recorded and assessed according to the IMWG
| Arm | Type | Description |
|---|---|---|
| BCMA CAR-T cells treat | EXPERIMENTAL | Patients will be be treated with BCMA CAR-T cells |
| Name | Type | Description |
|---|---|---|
| BCMA CAR-T cells | BIOLOGICAL | BCMA CAR-T cell therapy |
Inclusion Criteria: 1. Signed written informed consent; 2. Diagnose as relapsed /refractory multiple myeloma or other plasma cell disease, and meet one of the following conditions: 1. Failed to standard chemotherapy regimens; 2. Relapse after complete remission, high-risk and / or refractory...
Top 20 of 25 competitors
BCMA CAR-T cells is an investigational cell therapy being developed for the treatment of multiple myeloma, including relapsed or refractory multiple myeloma and plasma cell neoplasms. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BCMA CAR-T cells targets B-cell maturation antigen (BCMA), a protein expressed on malignant plasma cells in multiple myeloma. The therapy is designed to direct a patient's T cells to recognize and attack BCMA-expressing tumor cells.
BCMA CAR-T cells is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on Nasdaq under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial for this investigational therapy in multiple myeloma.
BCMA CAR-T cells is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by the FDA or other regulatory agencies and is still being evaluated for safety and efficacy in clinical trials.
BCMA CAR-T cells is being studied in one active Phase 1 clinical trial, identified as NCT04271644. This trial is recruiting patients with relapsed or refractory multiple myeloma and plasma cell disease, with an estimated enrollment of 80 participants in China.
BCMA CAR-T cells is a specific chimeric antigen receptor T-cell therapy targeting BCMA. It is distinct from other CAR-T therapies that target different antigens, such as CD19. This therapy is being developed by Precision BioSciences and is currently in Phase 1 testing for multiple myeloma.